Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Jefferies to hold a virtual conference » 04:55
11/19/20
11/19
04:55
11/19/20
04:55
MRNA

Moderna

$88.90 /

-4.225 (-4.54%)

, IMGN

ImmunoGen

$5.75 /

-0.035 (-0.61%)

, ESPR

Esperion

$29.18 /

-0.95 (-3.15%)

, CRL

Charles River

$234.11 /

-2.205 (-0.93%)

, AXGN

AxoGen

$15.16 /

-0.05 (-0.33%)

, INMD

InMode

$42.75 /

+0.16 (+0.38%)

, PRTA

Prothena

$12.10 /

-0.24 (-1.94%)

, SYNH

Syneos Health

$63.21 /

-0.24 (-0.38%)

, RDNT

RadNet

$18.19 /

-0.75 (-3.96%)

, OPNT

Opiant Pharmaceuticals

$7.95 /

+0.2 (+2.58%)

, FGEN

FibroGen

$41.56 /

-2.58 (-5.85%)

, MGLN

Magellan Health

$82.25 /

-2.47 (-2.92%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$15.66 /

-0.53 (-3.27%)

, IVA

Inventiva

$14.00 /

+ (+0.00%)

, ITOS

iTeos Therapeutics

$25.09 /

+1.14 (+4.76%)

, CLBS

Caladrius

$1.44 /

-0.055 (-3.68%)

, ALNA

Allena Pharmaceuticals

$1.37 /

-0.07 (-4.86%)

, SEEL

Seelos Therapeutics

$0.78 /

-0.0296 (-3.65%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$10.82 /

-0.23 (-2.08%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$29.18 /

-0.95 (-3.15%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$234.11 /

-2.205 (-0.93%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.75 /

+0.16 (+0.38%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.10 /

-0.24 (-1.94%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.19 /

-0.75 (-3.96%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+ (+0.00%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

Over a week ago
Conference/Events
Jefferies to hold a virtual conference » 04:55
11/18/20
11/18
04:55
11/18/20
04:55
MRNA

Moderna

$93.12 /

-4.88 (-4.98%)

, IMGN

ImmunoGen

$5.78 /

+0.03 (+0.52%)

, ESPR

Esperion

$30.13 /

+0.02 (+0.07%)

, CRL

Charles River

$236.30 /

-1.56 (-0.66%)

, AXGN

AxoGen

$15.29 /

+0.18 (+1.19%)

, INMD

InMode

$42.61 /

+0.8 (+1.91%)

, PRTA

Prothena

$12.34 /

-0.03 (-0.24%)

, SYNH

Syneos Health

$63.45 /

-0.37 (-0.58%)

, RDNT

RadNet

$18.94 /

-0.05 (-0.26%)

, OPNT

Opiant Pharmaceuticals

$7.78 /

-0.02 (-0.26%)

, FGEN

FibroGen

$44.14 /

+1.12 (+2.60%)

, MGLN

Magellan Health

$84.72 /

-0.64 (-0.75%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$16.19 /

+0.5 (+3.19%)

, IVA

Inventiva

$14.00 /

+0.175 (+1.27%)

, ITOS

iTeos Therapeutics

$23.95 /

-0.08 (-0.33%)

, CLBS

Caladrius

$1.50 /

-0.005 (-0.33%)

, ALNA

Allena Pharmaceuticals

$1.43 /

-0.15 (-9.49%)

, SEEL

Seelos Therapeutics

$0.81 /

-0.0119 (-1.45%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$11.04 /

+0.03 (+0.27%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$30.13 /

+0.02 (+0.07%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$236.30 /

-1.56 (-0.66%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.61 /

+0.8 (+1.91%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.34 /

-0.03 (-0.24%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.94 /

-0.05 (-0.26%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+0.175 (+1.27%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

Conference/Events
Jefferies to hold a virtual conference » 08:54
11/17/20
11/17
08:54
11/17/20
08:54
MRNA

Moderna

$97.95 /

+8.65 (+9.69%)

, IMGN

ImmunoGen

$5.75 /

-0.1 (-1.71%)

, ESPR

Esperion

$30.11 /

+1.45 (+5.06%)

, CRL

Charles River

$237.94 /

-0.75 (-0.31%)

, AXGN

AxoGen

$15.09 /

+0.445 (+3.04%)

, INMD

InMode

$41.88 /

-0.01 (-0.02%)

, PRTA

Prothena

$12.37 /

+0.07 (+0.57%)

, SYNH

Syneos Health

$63.82 /

+0.48 (+0.76%)

, RDNT

RadNet

$18.99 /

+0.43 (+2.32%)

, OPNT

Opiant Pharmaceuticals

$7.83 /

+0.045 (+0.58%)

, FGEN

FibroGen

$43.03 /

+0.79 (+1.87%)

, MGLN

Magellan Health

$85.23 /

+0.11 (+0.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$15.69 /

+0.28 (+1.82%)

, IVA

Inventiva

$14.00 /

-0.005 (-0.04%)

, ITOS

iTeos Therapeutics

$24.03 /

+0.36 (+1.52%)

, CLBS

Caladrius

$1.50 /

-0.01 (-0.66%)

, ALNA

Allena Pharmaceuticals

$1.58 /

+0.07 (+4.64%)

, SEEL

Seelos Therapeutics

$0.82 /

-0.0299 (-3.52%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$11.01 /

-0.05 (-0.45%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.82 /

-0.0299 (-3.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.99 /

+0.43 (+2.32%)

PRTA Prothena
$12.37 /

+0.07 (+0.57%)

OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

IVA Inventiva
$14.00 /

-0.005 (-0.04%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

INMD InMode
$41.88 /

-0.01 (-0.02%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CRL Charles River
$237.94 /

-0.75 (-0.31%)

CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
11/17/20 BMO Capital
Moderna downgraded to Market Perform from Outperform at BMO Capital
IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$30.11 /

+1.45 (+5.06%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$237.94 /

-0.75 (-0.31%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$41.88 /

-0.01 (-0.02%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.37 /

+0.07 (+0.57%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.99 /

+0.43 (+2.32%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

-0.005 (-0.04%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.82 /

-0.0299 (-3.52%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.99 /

+0.43 (+2.32%)

PRTA Prothena
$12.37 /

+0.07 (+0.57%)

OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

INMD InMode
$41.88 /

-0.01 (-0.02%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CRL Charles River
$237.94 /

-0.75 (-0.31%)

CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

IVA Inventiva
$14.00 /

-0.005 (-0.04%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

Hot Stocks
Charles River and PathoQuest to expand pact with NGS-based testing laboratory » 08:11
11/12/20
11/12
08:11
11/12/20
08:11
CRL

Charles River

$235.66 /

+6.96 (+3.04%)

PathoQuest and its…

PathoQuest and its strategic partner Charles River Laboratories International,, announced that it has established a U.S. subsidiary, PathoQuest,, and will construct a state-of-the-art next generation sequencing -based testing laboratory at Charles River's site in Wayne, PA. The establishment of this lab will enhance the strategic partnership between the two companies and will also expand Charles River's and PathoQuest's capabilities to meet client needs by providing a fully integrated and reliable solution for rapid viral safety testing of biologics, notably advanced therapeutic medicinal products and vaccines. The expanded relationship between PathoQuest and Charles River will offer North American biotechnology companies a NGS testing facility in the U.S. that identifies adventitious agents using PathoQuest's rapid, in vitro, comprehensive testing approach which accelerates development timelines of biologics without compromising safety and efficacy. This NGS approach can also be utilized for the genetic characterization of cell lines. The partnership between Charles River and PathoQuest provides clients with the most sensitive and rapid testing methodologies to help ensure the safety of products produced by the biopharmaceutical industry. Construction of PathoQuest's new office and laboratory facility is scheduled to begin in late 2020 with NGS services expected to be available in 2021. Once complete, the lab will be aligned with PathoQuest's existing lab in Paris and offer testing that adheres to Current Good Manufacturing Practices in accordance with U.S. Food and Drug Administration guidelines. This solution will offer the biopharmaceutical industry a comprehensive offering of testing services performed within the same facility, enabling rapid and reliable support for biologics development and quality control testing. Charles River's Wayne facility supports the development of biological products, including cell line characterization, viral safety, and viral clearance studies. Charles River has made an additional direct investment in PathoQuest to help fund the establishment of this new facility and to support the expansion of PathoQuest's testing platform into North America.

ShowHide Related Items >><<
CRL Charles River
$235.66 /

+6.96 (+3.04%)

CRL Charles River
$235.66 /

+6.96 (+3.04%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
CRL Charles River
$235.66 /

+6.96 (+3.04%)

Hot Stocks
Charles River CEO sells 22K shares of common stock » 17:07
11/03/20
11/03
17:07
11/03/20
17:07
CRL

Charles River

$237.97 /

+5.09 (+2.19%)

In a regulatory filing,…

In a regulatory filing, Charles River disclosed that its CEO James Foster sold 22K shares of common stock on November 2nd in a total transaction size of $5.11M. The holding represents about 8% of his total owned.

ShowHide Related Items >><<
CRL Charles River
$237.97 /

+5.09 (+2.19%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
CRL Charles River
$237.97 /

+5.09 (+2.19%)

Recommendations
Charles River price target raised to $256 from $237 at Truist » 08:37
11/03/20
11/03
08:37
11/03/20
08:37
CRL

Charles River

$232.88 /

+5.19 (+2.28%)

Truist analyst Sandy…

Truist analyst Sandy Draper raised the firm's price target on Charles River to $256 from $237 and keeps a Buy rating on the shares after its Q3 earnings beat. The analyst notes that it was a "strong quarter" for the company while its margin targets tracked one year ahead of expectations. Draper adds that Charles River has had a "strong history of operational excellence" and should continue to benefit from its "excellent" execution and "strong" tailwinds.

ShowHide Related Items >><<
CRL Charles River
$232.88 /

+5.19 (+2.28%)

10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
09/10/20 Jefferies
Charles River upgraded to Buy at Jefferies on faster than peer growth
CRL Charles River
$232.88 /

+5.19 (+2.28%)

Recommendations
Charles River price target raised to $250 from $235 at Deutsche Bank » 07:29
10/30/20
10/30
07:29
10/30/20
07:29
CRL

Charles River

$229.68 /

+7.7 (+3.47%)

Deutsche Bank analyst…

Deutsche Bank analyst George Hill raised the firm's price target on Charles River Laboratories to $250 from $235 and keeps a Buy rating on the shares following the company's better than expected Q3 results.

ShowHide Related Items >><<
CRL Charles River
$229.68 /

+7.7 (+3.47%)

09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
09/10/20 Jefferies
Charles River upgraded to Buy at Jefferies on faster than peer growth
09/10/20 Jefferies
Charles River upgraded to Buy from Hold at Jefferies
CRL Charles River
$229.68 /

+7.7 (+3.47%)

Earnings
Charles River sees low-to mid-single-digit percentage growth in Q4 non-GAAP EPS » 08:27
10/29/20
10/29
08:27
10/29/20
08:27
CRL

Charles River

$221.98 /

-7.15 (-3.12%)

Sees Q4 reported revenue…

Sees Q4 reported revenue growth year-over-year of high-single-digit, organic revenue growth year-over-year of mid- to-high-single-digit and non-GAAP EPS growth year-over-year low- to mid-single-digit vs. 4Q19. "Believe we are well positioned to finish the year strong and excited for the prospects as we look ahead into 2021 and beyond," the company said in an earnings slide presentation. Q4 consensus for EPS and revenue are $2.03 and $745.73M, respectively.

ShowHide Related Items >><<
CRL Charles River
$221.98 /

-7.15 (-3.12%)

09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
09/10/20 Jefferies
Charles River upgraded to Buy at Jefferies on faster than peer growth
09/10/20 Jefferies
Charles River upgraded to Buy from Hold at Jefferies
CRL Charles River
$221.98 /

-7.15 (-3.12%)

Earnings
Charles River raises FY20 EPS view to $7.75-$7.85 from $7.05-$7.35 » 07:12
10/29/20
10/29
07:12
10/29/20
07:12
CRL

Charles River

$221.98 /

-7.15 (-3.12%)

Consensus $7.26. Raises…

Consensus $7.26. Raises FY20 revenue growth view to 9.5%-10.5% from 7.5%-9%, consensus $2.85B. The company is increasing its 2020 financial guidance, which was previously provided on August 5, primarily as a result of the better-than-expected third quarter performance.

ShowHide Related Items >><<
CRL Charles River
$221.98 /

-7.15 (-3.12%)

09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
09/10/20 Jefferies
Charles River upgraded to Buy at Jefferies on faster than peer growth
09/10/20 Jefferies
Charles River upgraded to Buy from Hold at Jefferies
CRL Charles River
$221.98 /

-7.15 (-3.12%)

Earnings
Charles River reports Q3 EPS $2.33, consensus $1.80 » 07:11
10/29/20
10/29
07:11
10/29/20
07:11
CRL

Charles River

$221.98 /

-7.15 (-3.12%)

Reports Q3 revenue…

Reports Q3 revenue $743.3M, consensus $716.88M.James Foster, chairman, president and CEO, said, "Our exceptional third-quarter performance is indicative of several important factors: that our flexible and reliable outsourced solutions resonate with clients even more today than ever before; that our research model clients are already resuming their research activities; that the market environment remains robust; and that we are generating greater operating leverage across our businesses as a result of our efforts to build a more scalable and nimble organization."

ShowHide Related Items >><<
CRL Charles River
$221.98 /

-7.15 (-3.12%)

09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
09/10/20 Jefferies
Charles River upgraded to Buy at Jefferies on faster than peer growth
09/10/20 Jefferies
Charles River upgraded to Buy from Hold at Jefferies
CRL Charles River
$221.98 /

-7.15 (-3.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.